DENTSPLY SIRONA Reports 5% Decline in Q3 2025 Net Sales, Plans Restructuring

DENTSPLY SIRONA Inc. reported a decline in financial performance for the third quarter of 2025, with net sales of $904 million, down 5% from $951 million in the same period last year. For the nine months ending September 30, 2025, net sales totaled $2.719 billion, a decrease of 5.9% compared to $2.888 billion in 2024. The company experienced an operating loss of $218 million for the quarter, an improvement from a loss of $462 million in the prior year, while the net loss attributable to DENTSPLY SIRONA was $427 million, compared to a loss of $494 million in the same quarter of 2024.

The decrease in revenue was attributed to lower volumes in the Orthodontic and Implant Solutions segment, particularly due to the suspension of Byte sales, as well as declines in CAD/CAM, implants, and preventive products, especially in the United States. However, the company noted increased sales in treatment centers and endodontic consumables. The gross profit margin also fell to 48.8% from 52.1% year-over-year, primarily due to unfavorable product mix and pricing pressures, alongside tariff costs.

In terms of strategic developments, DENTSPLY SIRONA has been actively restructuring its operations. The company initiated a 2024 Plan aimed at improving operational performance, which includes a projected workforce reduction of 2% to 4% and is expected to yield annual cost savings of $80 million to $100 million. As of September 30, 2025, the company incurred $30 million in restructuring charges related to this plan. Additionally, the company has been implementing a new global Enterprise Resource Planning (ERP) system, which has contributed to short-term costs but is anticipated to enhance operational efficiency in the long run.

Operationally, DENTSPLY SIRONA reported a total employee headcount reduction as part of its restructuring efforts, with a focus on streamlining operations across its five global business units. The company also noted a significant increase in its inventory levels, which rose to $686 million from $564 million at the end of 2024, indicating a build-up in stock likely due to lower sales volumes. The company’s cash and cash equivalents increased to $363 million, up from $272 million at the end of 2024, reflecting improved liquidity.

Looking ahead, DENTSPLY SIRONA anticipates continued challenges due to macroeconomic conditions, including inflation and geopolitical tensions, which may impact consumer spending and clinician financing for equipment purchases. The company remains focused on mitigating these impacts through strategic pricing and sourcing initiatives. Despite the current challenges, DENTSPLY SIRONA is committed to maintaining its investment in research and development, aiming to sustain a level of investment at least 4% of annual net sales, as it seeks to innovate and enhance its product offerings in the dental and healthcare markets.